Teva has been trying to argue that their random mix of amino acids is different (even batches made by Teva are different) from others random mixes, adding to the issues of the Cop Wars.
As this is the World’s leading MS drug in terms of Sales, it is not surprising that other manufacturers want a slice of the pie. No wonder there are so many court cases with the generics companies,
Just think for every few months that production of the generics and sales are held up due to legal actions, how much is made on the sales. 6 months = $2 billion so bung a few million to patent lawyers is good business.
I think it shows safety and ease of monitoring for the neurologist, tops it over higher efficacy.
This event has been reported in the original glatiramer acetate but occurs rarely. Since approval, over 300 cases of Copaxone-associated liver-related abnormalities were reported to the United States Food and Drug Administration (US-FDA). I am sure if there are more we will hear of them
CoI: Some of authors have received funding in numerous ways from Teva…however their patients were using competitor drug